Stay updated with breaking news from Graphite Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Katherine Vega Stultz is the CEO and president of Ocelot Bio, a clinical-stage biotech company focused on the development of therapeutics to treat complications of end-stage liver disease.
Shares of Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) have earned an average rating of “Hold” from the nine analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and eight have assigned a hold recommendation to the company. The average 1-year price target among analysts […]
/PRNewswire/ -- DelveInsight's Sickle Cell Disease Market Insights report includes a comprehensive understanding of current treatment practices, sickle cell...
According to DelveInsight's estimates, the sickle cell disease market size in the 7MM is expected to show positive growth, during the forecast period (2023-2032), mainly attributed to the increasing
Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) – Equities research analysts at Cantor Fitzgerald decreased their FY2023 earnings estimates for shares of Graphite Bio in a research note issued on Tuesday, May 16th. Cantor Fitzgerald analyst O. Brayer now forecasts that the company will post earnings of ($0.99) per share for the year, down from […]